BioSig Signs Master Research Agreement with Cleveland Clinic to Explore Expanded Applications for its Digital Signal Processing Technology
October 24 2022 - 11:03AM
- Medical Center of Excellence to leverage the Company’s
PURE EP™ System to further its research and educational objectives
as a leader in cardiac electrophysiology
- Clinical investigations conducted by Cleveland Clinic
could expand clinical parameters of BioSig’s digital signal
processing technology for arrhythmia care
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”) an advanced digital signal processing technology company
delivering unprecedented accuracy and precision to intracardiac
signal visualization with its proprietary PURE EP™ System, today
announced that it will sponsor a research agreement with Cleveland
Clinic Foundation (CCF) to investigate expanded clinical
applications for the intracardiac signals acquired by its PURE EP™
System.
Under the terms of the research agreement, Cleveland Clinic will
conduct physician initiated scientific research investigating PURE
EP™’s potential to address common limitations of signal processing
and signal use expansion during— but not limited to—
electrophysiology ablation procedures. Results from this research
could elucidate new clinical workflow methods impacting the
ablation process for numerous arrhythmia types.
The Company has selected Cleveland Clinic, a leading medical
center of excellence, based on their world-class physician faculty,
research competency, and mutual interest in leveraging digital
signal processing technology to further advance the field of
cardiac electrophysiology.
“As a non-profit, research, education, and healthcare
institution, Cleveland Clinic has a long legacy of innovation in
cardiovascular disease, and specifically in the field of
electrophysiology. At BioSig, we embody their commitment to
clinical discovery and ensuring that optimal treatments are made
available to patients with efficiency and efficacy,” said Gray
Fleming, Chief Commercialization Officer, BioSig Technologies, Inc.
“We are honored to align ourselves with Cleveland Clinic’s
expertise as we discover new ways to positively impact procedural
workflows by leveraging digital signal processing technology.”
BioSig’s PURE EP™ System is currently under evaluation at both
Main and Fairview campuses of Cleveland Clinic’s Heart, Vascular
& Thoracic Institute.
About Cleveland Clinic
Cleveland Clinic is a nonprofit multispecialty academic medical
center that integrates clinical and hospital care with research and
education. U.S. News & World Report consistently names
Cleveland Clinic as one of the nation’s best hospitals in its
annual “America’s Best Hospitals” survey. As a leader in arrhythmia
treatment and diagnosis, Cleveland Clinic medical centers include
state-of-the-art electrophysiology laboratories, world-class
physicians and researchers, and the latest cutting-edge
technologies and protocols deployed for the treatment of heart
abnormalities. To learn more, visit clevelandclinic.org.
About BioSig Technologies
BioSig Technologies is an advanced digital signal processing
technology company bringing never-before-seen insights to the
treatment of cardiovascular arrhythmias. Through collaboration with
physicians, experts, and healthcare leaders across the field of
electrophysiology (EP), BioSig is committed to addressing
healthcare’s biggest priorities — saving time, saving costs, and
saving lives.
The Company’s first product, the PURE EP™ System, an FDA 510(k)
cleared non-invasive class II device, provides superior, real-time
signal visualization allowing physicians to perform insight-based,
highly targeted cardiac ablation procedures with increased
procedural efficiency and efficacy.
The PURE EP™ System is currently in a national commercial launch
and an integral part of well-respected healthcare systems, such as
Mayo Clinic, Texas Cardiac Arrhythmia Institute, Cleveland Clinic,
and Kansas City Heart Rhythm Institute. In a blinded clinical
study recently published in the Journal of Cardiovascular
Electrophysiology, electrophysiologists rated PURE EP™ as
equivalent or superior to conventional systems for 93.6% of signal
samples, with 75.2% earning a superior rating.
The global EP market is projected to reach $16B in 2028 with a
11.2% growth rate.[1]
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) market conditions and the
Company’s intended use of proceeds, (ii) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (iii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iv)
difficulties in obtaining financing on commercially reasonable
terms; (v) changes in the size and nature of our competition; (vi)
loss of one or more key executives or scientists; and (vii)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
1 Global Market Insights Inc. March 08, 2022.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road, 1st Floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jul 2023 to Jul 2024